
Samsung Bioepis' European Whitepaper Proposes Solutions to Bridge Policy Gaps that Hinder Healthy Market Competition and Timely Access to Biosimilar Medicines
Policies should take a patient-centric approach, positioning biosimilars as part of the solution to expand access, improve patient outcomes, ensure supply continuity, and strengthen system resilience.
Share
Biosimilars have played a significant role in alleviating the financial burden on the European healthcare system, having delivered €56 billion in cumulative cost savings across Europe over the past 11 years (2013-2024). 1 However, the current policy environment in Europe, particularly the post-launch pathways, is misaligned to incentivize biosimilar competition. With post-marketing challenges, on top of high development costs, many biologics will not face biosimilar competition at the point of loss of exclusivity (LoE) within the next decade.
The whitepaper proposes several measures to improve current practices that hinder healthy market competition and timely access to biosimilar medicines:
Health Technology Assessment (HTA) needs to be tailored for biosimilars: With its origin in innovative medicine, HTA is a multidisciplinary process that evaluates the medical, social, economic, and ethical implications of health technologies. Some countries often have oversimplified HTA requirements for biosimilars, where reimbursement decisions are solely based on price comparisons and do not take into account biosimilars' additional benefits or where the reference biologic is not reimbursed. In many cases, HTA is relevant, but with limited guidance to properly assess the biosimilar's value. HTA can be more streamlined and tailored to speed up the entry of biosimilars to the market.
In some countries, pricing and reimbursement (P&R) policies focus on achieving the lowest possible prices through mechanisms such as price linkage and reference pricing, thereby accelerating price erosion: Out of 28 European countries, 12 countries use external reference pricing methods and 17 countries mandate arbitrary discounts on biosimilar prices at an average of 28% below reference product. 2 Already set at significantly lower levels, biosimilar prices are driven further downward as competition begins, often leading to price erosion that drives players out of the market. Instead of arbitrary price-controls, free pricing will allow price discounts to be achieved naturally through free competition.
Tenders often favor a single-winner system and tend to overlook broader qualitative factors such as supply stability and quality assurance: National, regional, and local tenders should support supply diversification and fair competition through multi-winner systems, with greater transparency in communication and more periodic tender reopenings so that late entrants are also given opportunities to participate. Security and stability of supply should be given higher priority in tenders to enhance demand predictability and incentivize manufacturers to secure more robust supply chains.
Biosimilar uptake cannot be achieved without the support of physicians and pharmacists who prescribe and dispense these medicines: Incentives extended to healthcare professionals to encourage the prescribing and dispensing of biosimilars vary significantly across European countries. In some countries, prescriber incentives are misaligned, discouraging the use of biosimilar medicines. Incentive programs should be based on shared decision-making between physicians and patients, rather than automatic switching. Gainsharing can be introduced to stimulate biosimilar uptake while preserving competition and autonomy. Education programs for physicians, pharmacists, and patients should be continued to support wider use of biosimilars.
'Biosimilars are not one-size-fits-all, and establishing a sustainable framework for biosimilars requires a nuanced understanding of their heterogeneous applications across clinical settings. It is vital to tailor key solutions that address the unique challenges faced by different product types, prescribing patterns, and patient and disease characteristics. It is also important to consider the future viability of the market when reshaping policies, as the market needs clear signals of long-term sustainability to encourage continued investments in the biosimilar pipeline,' said Adam Levysohn, Vice President and Head of Commercial Strategy Europe, at Samsung Bioepis. 'It is important for healthcare systems to recognize that biosimilars are not merely a cost-saving tool for organizations. Policies should take a patient-centric approach, positioning biosimilars as part of the solution to expand access, improve patient outcomes, ensure supply continuity, and strengthen system resilience.'
Samsung Bioepis is a biopharmaceutical company that develops and manufactures high-quality biosimilars to accelerate patient access to biologic medicines. As a world leader in biosimilars, Samsung Bioepis has a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. Of the 11 biosimilars approved worldwide, eight products are available across Europe.
To access the report Solving the Biosimilar Void in Europe, please visit HERE.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – LinkedIn, X.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
TransLogic™ Showcases Modernization Solutions at Healthcare Facilities Conference
Advanced transport automation enhances patient care and reduces operational costs BROOMFIELD, Colo., July 29, 2025--(BUSINESS WIRE)--TransLogic™, a Swisslog Healthcare company and a leading supplier in transport automation, will demonstrate how modernizing operational technology optimizes healthcare facility operations at the 2025 Health Care Facilities Innovation Conference. The event, July 27-30 in Columbus, Ohio, brings together over 3,000 healthcare facility professionals focused on advancing safety and innovation in the healthcare-built environment. TransLogic will exhibit at booth #906 in the Exhibition Hall, showcasing solutions that streamline internal logistics and boost operational performance through innovations in transport automation. The conference features over 70 speakers and thought leaders, along with 300 exhibitors presenting the latest technologies in healthcare facility management. Attendees can explore TransLogic's Design Assist offering and discuss modernizations that address IT security for pneumatic tube systems. The Design Assist approach brings transport automation experts into the early design phases of hospital construction projects, fostering collaboration that enhances efficiency and ensures long-term serviceability. Modernizations directly address security concerns by upgrading current versions of software & firmware, and installing the most updated hardware that provide robust IT security provisions. "As healthcare facilities face mounting pressure to maximize resources, our trusted operational technology addresses these challenges head-on," said Adam Tappen, Senior Vice President of Sales and Service at TransLogic North America. "Our pneumatic tube systems, proudly made in the USA, offer tangible benefits that facility managers can implement to transform their operations and enhance overall healthcare delivery through thorough early planning, consistent maintenance, and system updates." TransLogic will highlight the significant impact of its systems on healthcare operations. Company research shows that in a 300-bed hospital, a well-designed pneumatic tube system can save approximately $1.3 million annually in courier labor costs, with nurses spending 22% less time searching for missing medications. "The second half of 2025 promises exciting developments for healthcare facilities as we continue to advance visibility into hospital pneumatic tube systems," said Scott Fincher, Product Director, Transport Automation at TransLogic and Swisslog Healthcare. "We'll soon be able to introduce a solution that not only meets today's challenges but anticipates tomorrow's needs, especially in the day-to-day happenings with our facilities partners." For more information about TransLogic and its offerings, visit About Swisslog Healthcare Swisslog Healthcare provides pharmacy workflow automations through robotic solutions and operational technology that enable hospitals and health systems to assist providers in treating patients across the continuum of care. Integrating transport and pharmacy automation, value-added services, and intelligent software, Swisslog Healthcare enables healthcare providers to respond to patients' needs quickly and with greater accuracy. The company minimizes many sources of operational waste, so providers achieve higher levels of productivity to impact the well-being of patients in positive ways. For more information, visit About TransLogic™ TransLogic™, a Swisslog Healthcare Company, builds on its 100 years of operational technology expertise to reliably automate the delivery of critical items and leverage innovations which transcend industry standards in transport automation. TransLogic™ products are manufactured in the USA, resulting in nominal supply chain issues, fewer shipping delays, and quality controls which meet North America's standards. Learn more about TransLogic™ solutions at View source version on Contacts Media Contacts Erica Fetherston10 to 1 Public Relationserica@ (480) 676-9141 Emily Cardone10 to 1 Public Relationsemily@ (480) 245-3983 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
7 minutes ago
- Business Wire
TransLogic™ Showcases Modernization Solutions at Healthcare Facilities Conference
BROOMFIELD, Colo.--(BUSINESS WIRE)-- TransLogic™, a Swisslog Healthcare company and a leading supplier in transport automation, will demonstrate how modernizing operational technology optimizes healthcare facility operations at the 2025 Health Care Facilities Innovation Conference. The event, July 27-30 in Columbus, Ohio, brings together over 3,000 healthcare facility professionals focused on advancing safety and innovation in the healthcare-built environment. TransLogic will exhibit at booth #906 in the Exhibition Hall, showcasing solutions that streamline internal logistics and boost operational performance through innovations in transport automation. The conference features over 70 speakers and thought leaders, along with 300 exhibitors presenting the latest technologies in healthcare facility management. Attendees can explore TransLogic's Design Assist offering and discuss modernizations that address IT security for pneumatic tube systems. The Design Assist approach brings transport automation experts into the early design phases of hospital construction projects, fostering collaboration that enhances efficiency and ensures long-term serviceability. Modernizations directly address security concerns by upgrading current versions of software & firmware, and installing the most updated hardware that provide robust IT security provisions. "As healthcare facilities face mounting pressure to maximize resources, our trusted operational technology addresses these challenges head-on," said Adam Tappen, Senior Vice President of Sales and Service at TransLogic North America. "Our pneumatic tube systems, proudly made in the USA, offer tangible benefits that facility managers can implement to transform their operations and enhance overall healthcare delivery through thorough early planning, consistent maintenance, and system updates." TransLogic will highlight the significant impact of its systems on healthcare operations. Company research shows that in a 300-bed hospital, a well-designed pneumatic tube system can save approximately $1.3 million annually in courier labor costs, with nurses spending 22% less time searching for missing medications. "The second half of 2025 promises exciting developments for healthcare facilities as we continue to advance visibility into hospital pneumatic tube systems," said Scott Fincher, Product Director, Transport Automation at TransLogic and Swisslog Healthcare. "We'll soon be able to introduce a solution that not only meets today's challenges but anticipates tomorrow's needs, especially in the day-to-day happenings with our facilities partners." For more information about TransLogic and its offerings, visit About Swisslog Healthcare Swisslog Healthcare provides pharmacy workflow automations through robotic solutions and operational technology that enable hospitals and health systems to assist providers in treating patients across the continuum of care. Integrating transport and pharmacy automation, value-added services, and intelligent software, Swisslog Healthcare enables healthcare providers to respond to patients' needs quickly and with greater accuracy. The company minimizes many sources of operational waste, so providers achieve higher levels of productivity to impact the well-being of patients in positive ways. For more information, visit About TransLogic™ TransLogic™, a Swisslog Healthcare Company, builds on its 100 years of operational technology expertise to reliably automate the delivery of critical items and leverage innovations which transcend industry standards in transport automation. TransLogic™ products are manufactured in the USA, resulting in nominal supply chain issues, fewer shipping delays, and quality controls which meet North America's standards. Learn more about TransLogic™ solutions at
Yahoo
2 hours ago
- Yahoo
How will Trump's E.U. tariffs affect drug prices?
President Donald Trump's trade deal with the European Union may lead to higher prices for brand-name drugs in the United States, including blockbuster medications like Ozempic and Wegovy, experts say. The trade deal, announced Sunday, places a 15% tariff on most imported goods from the E.U., including pharmaceuticals. While that comes in well below the 200% tariffs Trump had threatened on pharmaceutical imports earlier this month, it'll still have an impact. Pharmaceuticals are the United States' fifth largest import, said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School. Europe is a major manufacturing hub for brand-name drugs in particular. Nearly half of the active ingredients for brand-name drugs taken in the United States are produced in European countries such as Ireland, Germany, Italy and Belgium, Kesselheim said. Europe is also where many drugmakers do final steps, such as filling and packaging. Novo Nordisk's diabetes and obesity drugs Ozempic and Wegovy are both produced in Denmark. Botox, made by Allergen, and the cancer drug Keytruda from drugmaker Merck are made in Ireland. (In recent years, however, more of Keytruda's manufacturing has shifted to the United States.) While brand-name drugs only account for about 10% of prescriptions filled in the United States, they make up about 80% of all drug spending, Kesselheim said. 'That's because they're priced so high,' he said. 'Each individual [generic] statin is pennies, whereas Botox is thousands to tens of thousands of dollars.' In the short term, drug companies might increase the list prices of these products to account for the higher cost, said Rena Conti, an associate professor at Boston University's Questrom School of Business. 'U.S. consumers will pay more at the pharmacy counter for these drugs,' Conti said. 'What patients pay at the pharmacy counter reflects drug companies' set price list.' Kesselheim said it's an open question whether patients would even notice the higher prices, given that brand-name drugs are already so expensive. 'The drug prices are already two to three times higher in the United States than they are in other countries,' he said. 'There is a lot more room for drug companies [to charge more.]' Generic drugs, on the other hand, are often sold at close to the cost that they're made. About 9 out of 10 prescription drugs taken in the United States are generics, Kesselheim added. The Pharmaceutical Research and Manufacturers of America, a drug industry trade group, did not immediately respond to a request for comment. The E.U. tariffs aren't expected to affect the prices of many generic drugs. Some generic drugs are made in Europe, but the majority are manufactured in countries like China and India, said Arthur Caplan, the head of the division of medical ethics at NYU Langone Medical Center in New York City. There have been concerns that tariffs on these countries could drive up the cost of generic drugs and exacerbate drug shortages. Generic drugs aren't a lucrative enough business for companies to invest in new manufacturing facilities in the United States, Caplan said. A spokesperson for the Association for Accessible Medicines, a trade group that represents generic drugmakers, said the group is still assessing the potential impact of the tariffs as well as the specifics of the trade deal. This article was originally published on Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información